Navigation Links
Novavax Reports Second Quarter 2009 Financial Results
Date:8/7/2009

oration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

                                   NOVAVAX, INC.
                       CONSOLIDATED STATEMENTS OF OPERATIONS
               (in thousands, except share and per share information)
                                   (unaudited)

                                    Three months ended      Six months ended
                                        June 30,                June 30,
                                        --------                --------
                                    2009      2008          2009       2008
                                    ----      ----          ----       ----
    Revenues                           29        342           50         800
                                       --        ---           --         ---

    Operating costs and
     expenses:
       Research and development     5,297      5,380        9,563     
'/>"/>
SOURCE  Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 

Related biology technology :

1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
5. Novavax Announces Repayment of $5 Million of Convertible Debt
6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
8. Novavax Appoints Stanley Erck to Board of Directors
9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 The Center for ... Communications, is pleased to announce the full ... Accounting and Reporting Congress . The forum ... on March 16-17, 2010. ,, Over 1,500 ... have attended this premier event since its ...
(Date:12/15/2009)... Office has announced the launch of several innovative new ... services in the current economic climate. The first ... to finance legal services over a period of 6, ... in their start-up companies. The second is aimed ... payment arrangements over 6 to 12 month period at ...
(Date:12/14/2009)... Patrick Kennedy Joins with State Biotech Leaders ... in Research and Development while Boosting Rhode ... ,, PROVIDENCE, R.I., Dec. 14 /PRNewswire-USNewswire/ ... leaders in research, medicine and biotechnology gathered ... to discuss the importance of medical innovation ...
(Date:12/14/2009)... CARLOS, Calif., Dec. 14 Nektar Therapeutics ... Winger has been appointed to serve on its ... biopharmaceutical industry leader with over 35 years of ... ,, "Dennis brings to Nektar extensive industry perspective ... said Howard W. Robin, President and CEO of ...
Breaking Biology Technology:CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3
... SPO Medical Inc. (OTC:,SPOM - News), a leading ... monitoring devices, announced today that it,has appointed Med Tech ... group for the US market. , ... independent sales,organizations serving the healthcare industry and operate with ...
... stem cells and accelerates development of proprietary enhanced ... the introduction of its GT(TM) Flow Transfection System ... be held in New York, NY. The MaxCyte ... technology for customizing the biological activity of cells ...
... Inc., a clinical-stage biopharmaceutical company focused on diseases ... a Small Business Innovation Research (SBIR) Phase I ... Infectious Diseases (NIAID), National Institutes of Health (NIH), ... novel tuberculosis (TB) lead dipiperidine drug compound, SQ609. ...
Other Biology Technology:SPO Medical Appoints New US Sales Rep Groups 2SPO Medical Appoints New US Sales Rep Groups 3MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 2MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 3Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609 2Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609 3
(Date:12/16/2009)... Dec. 1 GestureTek Inc. today ... 3.0 - a turnkey, portable, plug and ... exhibits, entertainment and touring promotions. GestureTek is ... patents in camera-enabled gesture recognition technology for ... Guaranteed for quality, the CUBE has TUV, ...
(Date:12/16/2009)... N.J., Dec. 3 BIO-key International, ... in wireless public safety and finger-based biometric ... its shareholders at a Special Shareholder Meeting ... company,s Law Enforcement Division to Interact911 Mobile ... were cast in favor and 1.2% were ...
(Date:12/16/2009)... BIO-key International, Inc. (OTC Bulletin Board: BKYI), ... today announced that SC Magazine, one of ... BIO-key International the 2009 Innovator of the ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) ,, ... Magazine, "Biometric providers have been trying for ...
Breaking Biology News(10 mins):GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11 2009 53666 1BioSpecifics Technologies Corp to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12 2009 13362 1BioSpecifics Technologies Corp to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12 2009 13362 2DNA Helps Reunite Children With Their Families 4823 1DNA Helps Reunite Children With Their Families 4823 2DNA Helps Reunite Children With Their Families 4823 3
... HealthSystem (NorthShore) and Northwestern University have discovered that fiber ... measure blood levels in the colonic lining (mucosa) in ... colon cancer. , The study appears in the ... journal of the American Gastroenterological Association (AGA) Institute. ...
... WI, September 29, 2008 -- Combating soil erosion is a ... many have incorporated conservation tillage systems in their effort to ... are an important tool in this cycle, and while it ... biomass, the resulting levels of nitrogen for the following cash ...
... Sirtris, a GSK company focused on discovering and ... such as Type 2 Diabetes, announced today that it ... of sirtuin research and its potential to treat diseases ... inflammation, cancer, and heart disease. Entitled "SIRTUINS ...
Other Biology News:Breakthrough optical technology to assess colon cancer risk, accuracy 2Breakthrough optical technology to assess colon cancer risk, accuracy 3Nitrogen applied 2Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery 2
... for complex protein processing and production challenges. We ... you develop a solution to your problem and then ... do additional work/scale-up processes ... transfer all methodology to your own lab , ...
... GeneSpring Workgroup solution is a highly ... mining expression data in a workgroup ... deployed in over 40 leading pharmaceutical, ... worldwide. GeneSpring Workgroup streamlines genomics research ...
... genome-wide microRNA (miRNA) expression profiling service using ... enable highly sensitive and specific direct detection ... for mature miRNA of all species available ... miRBase database (Release 8.2). Our service is ...
... ProXPRESS 2D Proteomic Imaging System, Basic ... Over a Wide Dynamic Range: The ProXPRESS ... sensitive in imaging system for both proteomic ... 2D provides unparalleled flexibility, enabling the use ...
Biology Products: